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Abstract
Genome-wide association studies identified single nucleotide polymorphisms (SNPs) in the nicotinic acetylcholine receptors
(nAChRs) cluster as a risk factor for nicotine dependency and COPD. We investigated whether SNPs in the nAChR cluster are
associated with smoking habits and lung function decline, and if these potential associations are independent of each other.
The SNPs rs569207, rs1051730 and rs8034191 in the nAChR cluster were analyzed in the Vlagtwedde-Vlaardingen cohort
(n=1,390) that was followed for 25 years. We used GEE and LME models to analyze the associations of the SNPs with
quitting or restarting smoking and with the annual FEV1 decline respectively. Individuals homozygote (CC) for rs569207
were more likely to quit smoking (OR (95%CI)=1.58 (1.05–2.38)) compared to wild-type (TT) individuals. Individuals
homozygote (TT) for rs1051730 were less likely to quit smoking (0.64 (0.42; 0.97)) compared to wild-type (CC) individuals.
None of the SNPs was significantly associated with the annual FEV1 decline in smokers and ex-smokers. We show that SNPs
in the nAChR region are associated with smoking habits such as quitting smoking, but have no significant effect on the
annual FEV1 decline in smokers and ex-smokers, suggesting a potential role of these SNPs in COPD development via
smoking habits rather than via direct effects on lung function.
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Introduction
Cigarette smoking is a major concern influencing public health
worldwide. It is the main risk factor for Chronic Obstructive
Pulmonary Disease (COPD), but the risk to develop airway
obstruction varies between smokers due to differences in genetic
susceptibility.
Over time, studies in animal models [1,2], candidate gene or
family and twin studies [3,4] have tackled the underlying
mechanisms and genetic background influencing nicotine addic-
tion and smoking habits [5]. Recent reviews highlighted the
important role of genetic factors in the inter-individual variation to
initiate, maintain or to quit smoking and their effects on lung
function [6,7].
The genetic contribution to the variation in smoking behaviour
recognizes two classes of genes: genes influencing the response to
nicotine, like nicotinic acetylcholine receptors (nAChR) and
nicotine metabolism (CYP2D6), and genes predisposing to
addictive behaviour due to their effects on key neurotransmitter
pathways like dopamine (DRD1) and serotonin (TPH) [8].
Nicotinic acetylcholine receptor (nAChR) is a controversial gene with
respect to its association with COPD and smoking addition. Single
nucleotide polymorphisms (SNPs) rs1051730 and rs8034191 in the
nAChR cluster have been identified in cross-sectional genome-wide
association (GWA) studies as a risk for COPD [9]. Furthermore,
studies showed cross-sectional associations of the SNPs in the
nAChR cluster with nicotine dependency based on the reported
number of cigarettes per day [10] or the Fagerstrom Test of
Nicotine Dependence (FTND), a test reliably predicting smoking
cessation and correlating with biochemical measurements of
nicotine dependency [11]. Other studies have found a cross-
sectional association of the same variants with the level of lung
function and COPD [12].
Since smoking is a risk factor for COPD itself, it is not clear
from these cross-sectional studies whether these SNPs in the
nAChR cluster are directly and independently a risk for COPD
development or whether they are associated with COPD through
their association with nicotine dependency and smoking habits
[10,11,13].
We had the unique opportunity to study longitudinally the
association of the nAChR variants with changes in smoking habits
and lung function in the population-based Vlagtwedde-Vlaardin-
gen cohort.
Results
The clinical characteristics of the Vlagtwedde-Vlaardingen
cohort are presented in table 1.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33386The 3 SNPs in the nAChR cluster rs1051730, rs8034191 and
rs569207 were all in Hardy Weinberg Equilibrium (p.0.05) and
their prevalence was relatively high (9% to 57%; Table S1).
1. SNPs in the nAChR cluster and changes in smoking
habits in smokers and ex-smokers
In smokers, individuals homozygote variant (CC) for rs569207
were more likely to quit smoking (OR (odds ratio) (95%CI
(confidence interval))=1.58 (1.05–2.38)) compared to wild type
(TT) individuals (Figure 1, upper graph). Individuals homozygote
variant (TT) for rs1051730 were more likely to continue smoking
(OR (95%CI)=0.64 (0.42–0.97)) compared to wild type (CC)
individuals (Figure 1, upper graph). The rs8034191 SNP was not
associated with quitting smoking. None of the SNPs were
associated with restarting smoking (Figure 1, lower graph).
Heterozygotes showed no significant associations compared to
wild-types. Detailed data on these associations are presented in the
supplementary material (Table S2).
2. SNPs in the nAChR cluster and annual FEV1 decline in
smokers and ex-smokers
The numbers of available FEV1-pairs in smokers and ex-
smokers are presented in the supplementary material (Table S3).
None of the SNPs was significantly associated with the annual
FEV1 decline in smokers or ex-smokers, with or without correction
for quitting and restarting smoking, respectively (Table 2). Also,
there was no association between the SNPs and the annual FEV1
decline in never smokers (Table 2). Additionally we investigated
the associations of smoking status with the decline in annual FEV1
using an LME model, independent of the genotypes. There was a
significant difference in annual FEV1 decline between smokers and
never smokers and between smokers and ex-smokers independent
of the genotypes. Detailed results are presented in the data
supplement Table S4.
3. Smoking habits and annual FEV1 decline in smokers
and ex-smokers
Subjects who quitted smoking had (B (regression coefficient)
(95%CI)=20.3 ml (9.49–31.15)) significantly less FEV1 decline
per year than subjects who continued smoking. Ex-smokers who
restarted smoking had a faster FEV1 decline (B
(95%CI)=214.7 ml (231.5 - 2.1)) per year than ex-smokers
who did not restart smoking, although this did not reach
significance.
4. SNPs in the nAChR cluster and cigarettes smoked per
day, packyears, and COPD at the last survey
In current smokers none of the SNPs was significantly associated
with the number of cigarettes smoked per day at the last survey
(Table 3).
In current and ex-smokers, only individuals homozygote variant
(CC) for rs569207 had a lower number of packyears (B
(95%CI)=25.9 (211.5 - 20.3)) at the last survey as compared
to wild-type (TT) individuals (Table 3).
Discussion
The nAChRs are highly expressed in the nervous system and
their binding to nicotine activates physiological and pharmaco-
logical responses to tobacco smoking [11]. Variants in the nAChR
cluster have been associated with nicotine dependency and
smoking status [10,11,14]. So far, studies showed cross-sectional
associations of the nAChR variants with nicotine dependency and
the level of lung function and COPD [10–12,15–18]. Since
smoking is a risk factor for COPD itself, cross-sectional studies can
not elucidate whether the effect of the nAChR variants determine
COPD development directly or indirectly via smoking addiction.
Our longitudinal study shows that rs1051730 and rs569207 in
the nAChR are associated with an increased and decreased ability
to quit smoking, respectively, but the SNPs are not associated with
the annual FEV1 decline. This suggests that these SNPs may be
involved in COPD development via smoking habits rather their
effect on (accelerated) lung function decline (Figure 2).
First, we observed in smokers that individuals homozygote
variant (CC) for rs569207 were more likely to quit smoking
compared to wild type (TT) individuals. This is compatible with a
previous study showing that the haplotype for rs569207 confers
protective effects on nicotine addiction compared with haplotypes
for other SNPs within the same Linkage Disequilibrium (LD) block
[13]. We additionally found that individuals homozygote variant
(TT) for rs1051730 were less likely to quit smoking compared to
wild type (CC) individuals, a finding that is in line with a previous
study [10]. Although r
2 between rs569207 and rs1051730 was only
0.11 in our study population (Figure S1), we observed that
individuals having the homozygote variant for rs569207 are also
the ones who have the wild type for rs1051730 (and thus are less
likely to quit smoking), strengthening our findings of a protective
effect of the variant in rs569207 for smoking habits within the
nAChR cluster. Rs1051730 and rs8034191 were highly correlated
(r
2=0.91), yet rs8034191 was not associated with quitting smoking
among smokers, suggesting that other factors at the subject’s level
might explain the significant association of rs1051730 with the
Table 1. Clinical characteristics of the Vlagtwedde-
Vlaardingen cohort at the last survey.
Vlagtwedde-Vlaardingen
cohort (n=1,390)
Duration of follow-up (years) 21 (16–22)
Median nr. of visits 7 (5–8)
Males, number (%) 714 (51.4)
Age (years)* 52 (43–60)
Height (cm) 170.3 (9.3)
Never smokers, number (%) 445 (32.0)
Ex-smokers, number (%) 456 (32.8)
Current smokers, number (%) 489 (35.2)
Packyears * 8.9 (0–24)
FEV1 (L) 2.8 (0.7)
VC (L) 3.8 (0.9)
FEV1/VC (%) 73.8 (8.9)
FEV1 (% predicted) 92.6 (15.4)
FEV1 change (ml/year) 220.8 (22.9)
No COPD, number (%) 993 (73.8)
COPD, GOLD stage I, number (%) # 185 (13.8)
COPD, GOLD stage II, number (%) # 146 (10.9)
COPD, GOLD stage III, number (%) # 21 (1.6)
Data are presented as mean (standard deviation) or * median (range);
FEV1=forced expiratory volume in one second; VC=vital capacity;
COPD=Chronic Obstructive Pulmonary Disease; GOLD=Global Initiative for
Chronic Obstructive Lung Disease; GOLD stage I=mild COPD; GOLD stage
II=moderate COPD; GOLD stage III=severe COPD; # According to ATS/ERS
standards [35].
doi:10.1371/journal.pone.0033386.t001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33386Figure 1. SNPs in the nAChR cluster and OR (95%CI) for quitting smoking in subjects who smoke (upper graph), and OR (95%CI) for
restarting to smoke in ex-smokers (lower graph). Nr. of pairs=number of paired observations in which the subject stopped respectively
restarted smoking/ total number of paired observations included in the analysis; Circles represent the odd ratio (OR) and vertical bars represent 95%
confidence interval (CI); Wild type was set to one as the reference category; Different total number of paired observations for the SNP genotypes are
due to missing data on genotype or smoking habits. The analyses are adjusted for gender and the time between 2 successive surveys. rs569207
TT=wild-type, TC=heterozygote, CC=homozygote variant rs1051730 CC=wild-type CT=heterozygote TT=homozygote variant rs8034191
GG=wild-type, GA=heterozygote, AA=homozygote variant.
doi:10.1371/journal.pone.0033386.g001
Table 2. SNPs in the nAChR cluster and annual FEV1 decline (ml/year) in smokers, ex-smokers and never smokers.
SNPs annual FEV1 decline (smokers)
1 annual FEV1 decline (ex-smokers)
2 annual FEV1 decline (never smokers)
3
B 95%CI p B 95%CI p B 95%CI p
rs569207 a0 . 3 27.6–8.3 0.939 4.1 26.4–14.5 0.451 2.6 25.5–10.6 0.531
b 13.1 25.7–31.9 0.172 0.9 215.9–17.8 0.916 2.9 213.7–19.7 0.727
rs1051730 a0 . 1 27.8–8.1 0.973 22.4 212.3 – 7.6 0.643 25.3 213.1 - 2.6 0.189
b5 . 4 28.2–18.9 0.437 3.9 214.3–22.2 0.674 20.7 215.1 - 13.6 0.925
rs8034191 a 21.1 29.2 – 7.1 0.919 20.3 210.2 – 9.8 0.964 23.6 211.4 - 4.3 0.370
b3 . 9 29.6–17.4 0.405 5.4 211.5–22.3 0.531 24.8 218.6 - 9.1 0.499
B=regression coefficient from the linear mixed-effect model, adjusted for 1=quitting smoking, 2=restarting smoking, 3=never smoker, gender, height and age at the
first of two successive surveys and time between two successive surveys. ‘‘Smokers’’ refer to those paired observations in which the subject was a smoker at the first of
two successive surveys and quitted smoking or continued smoking at the nearest follow-up survey. ‘‘Ex-smokers’’ refer to those paired observations in which the subject
was an ex-smoker at the first of two successive surveys and continued being an ex-smoker or restarted smoking at the nearest follow-up survey. ‘‘Never smoker’’ refer to
those paired observations in which the subject was a never smoker at the first of two successive surveys and continued being a never smoker at the nearest follow-up
survey. a=heterozygotes vs. wild-type; b=homozygote variant vs. wild-type.
doi:10.1371/journal.pone.0033386.t002
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encode an actual receptor protein, we have selected this SNP for
analyses with smoking habits since it has been identified in a
previous GWA study as a risk for COPD [9].
Second, none of the nAChR SNPs was significantly associated
with annual FEV1 decline in smokers or ex-smokers and neither
with annual FEV1 decline in never smokers. Additionally, none of
the SNPs was significantly associated with the level of FEV1
among smokers, ex-smokers and never smokers (data not shown).
Pillai et al performed a GWA study in four independent
populations and demonstrated that the 15q/25 region is associated
with COPD defined by airway obstruction [9]. The authors
suggested that the rs1051730 (CHRNA3) or rs8034191
(LOC123688) are causal variants for COPD [19]. In line with
this, rs1051730 and rs8034191 were found to be associated with
lower levels of FEV1 in the British 1958 birth cohort. However, the
latter two studies looked into cross-sectional level of FEV1, and
thus they cannot disentangle whether the SNPs act via nicotine
dependency, or have independent effects. Our longitudinal data
strongly suggest that these SNPs are not associated with lung
function decline since we found no effect of the SNPs on FEV1
decline, and additionally that this lack of effect was independent of
smoking.
Third, we observed that smokers who quit smoking had less
annual FEV1 decline compared with subjects who continued
smoking. Our findings are consistent with the results from previous
studies demonstrating in a smoking cessation program that quitters
had less FEV1 decline compared with persistent smokers with
COPD [20].
Results of two independent cohorts showed that rs1051730 is
additionally associated with emphysema, a feature of COPD, but
not with nicotine addiction when defined as the number of
packyears smoked [12]. We also found that neither rs1051730 nor
rs8034191 were associated with the number of packyears smoked
at the last survey suggesting that the number of packyears does not
necessarily reflect addiction. Interestingly, in current and ex-
smokers homozygote variant (CC) for rs569207 had a lower
number of packyears at the last survey than wild type (TT)
individuals. This may reflect that carriers of this variant are able to
quit smoking more easily, highlighting the consistency of our
results.
Our longitudinal results draw the attention to rs569207 in the
CHRNA5 gene. This SNP showed a protective effect in relation to
smoking habits in the general population, without an effect on
annual FEV1 decline. This clearly suggests that rs569207 has a
protective effect on COPD development via smoking habits
exclusively and not via lung function decline (Figure 2). This
increased likelihood of quitting smoking was previously seen in
individuals carrying CYP2A6 variants [21]. CYP2A6, the gene that
influences the response to nicotine besides nAChRs, is responsible
for the metabolic inactivation of nicotine to cotinine [22]. It is
tempting to speculate that as for CYP2A6 variants, individuals
carrying rs569207 do not build up a tolerance to nicotine which is
thought to play a critical role in the development and maintenance
of nicotine dependency. However, this seems to be unlikely since
rs569207 is located in intron 1 and might not have effects other
than the regulation of the gene/protein expression. So, from the
current study we can not draw firm conclusions on the biological
effects of the SNPs in nAChR cluster and future functional studies
should focus on this in detail. Moreover, pre-clinical studies have
demonstrated that bupropion is a non-competitive antagonist at
the nAChRs subunits [23–25] and thus it is plausible that genetic
Table 3. SNPs in the nAChR cluster with cigarettes smoked per day in current smokers, and packyears in ever smokers at the last
survey.
SNP
cigarettes/day
in current smokers*
packyears
in ever smokers**
B 95%CI p-value B 95%CI p-value
rs569207 a 21.5 23.3 - 0.4 0.111 21.5 24.1 - 1.0 0.238
b 22.8 27.6 - 2.0 0.252 25.9 211.5 - 20.3 0.039
rs1051730 a1 . 1 20.6–2.9 0.207 0.1 22.4–2.6 0.943
b 21.5 24.6 - 1.6 0.338 0.3 24.1–4.7 0.901
rs8034191 a0 . 2 21.6–2.0 0.819 20.7 23. - 1.9 0.600
b 21.2 24.3 - 1.9 0.469 20.6 24.8 - 3.7 0.800
B=regression coefficient derived from linear regression model, adjusted for age and gender;
*only current smokers at the last survey;
**ever smokers are current smokers and ex-smokers together.
a=heterozygote vs. wild-type.
b=homozygote variant vs. wild-type.
doi:10.1371/journal.pone.0033386.t003
Figure 2. Summary of the observed associations in the current
study. SNPs=single nucleotide polymorphisms; COPD=Chronic Ob-
structive Pulmonary Disease; nAChR=nicotinic acetylcholine receptor;
+=association; 2=no association.
doi:10.1371/journal.pone.0033386.g002
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of tobacco dependence [25]. It has been shown that rs871058, an
intronic SNP in CHRNA5, appears to have pharmacogenetic
relevance [25]. This intronic SNP rs871058 is highly correlated
with rs16969968 in CHRNA5. The latest emerged as the strongest
risk variant in a nicotine dependence association study of over
3,000 SNPs in over 300 candidate genes [14,25]. Therefore, it
might be that the intronic SNP, rs569207, from the current study
is in strong linkage disequilibrium with other SNPs that are able to
alter the subunit properties or even have a pharmacological effect,
since there is a high degree of linkage disequilibrium across
CHRNA5 [25]. Based on our data we can not state that our
observations are the results of monogenic effects. Furthermore,
pharmacogenetic variation can significantly alter susceptibility to,
and response to treatment for, drug dependence [26]. In a recent
study it has been hypothesized that slower nicotine metabolism, as
measured by the nicotine metabolite ratio, would decrease the
influence of genotypes for rs16969968, rs1051730 in CHRNA5 and
rs578776 in CHRNA3 [27]. The authors found, in a sample of
1030 treatment seekers, significant independent and additive
associations of nicotine metabolite ratio, rs16969968, and
rs1051730 with cigarettes per day, but the interactions of the
nicotine metabolite ratio with genotype on cigarettes per day were
not significant [27]. A recent randomized clinical trial of nicotine
replacement therapy showed that fast nicotine metabolizers are
less likely to succeed at quitting smoking, as compared to slow
nicotine metabolizers, when offered free nicotine patches [28].
This is the first longitudinal study suggesting that SNPs in the
nAChR cluster potentially have a causal role in COPD via smoking
habits. We hypothesize therefore that these variants are related to
the onset of COPD via their association with smoking habits, and
they are not independently related to COPD development.
Methods
Ethics Statement
The study protocol was approved by the local university medical
hospital ethics committee, University Medical Center Groningen,
University of Groningen, The Netherlands and all patients gave
their written informed consent. In 1984, the Committee on
Human Subjects in Research of the University of Groningen
reviewed the study and affirmed the safety of the protocol and
study design (http://www.ccmo-online.nl/main.asp?pid=14&
sid=16&ssid=33&inid=16).
Study population
The Vlagtwedde-Vlaardingen cohort (n=1390) has been
previously described in detail [29,30]. The cohort was prospec-
tively followed for 25 years with lung function measurements every
3 years using a water-sealed spirometer (Lode Intruments, the
Netherlands). Lung function was determined by measurement of
the Forced Expiratory Volume in 1 second (FEV1). The median
number of surveys during the follow-up was 7. Current, ex-
smokers and never smokers definition is based on validated
questionnaires. A current smoker has been defined as having
smoked in the previous 12 months and an ex-smoker as not having
smoked in the previous 12 months.
Selection and genotyping of the SNPs in the nAChR
cluster
We selected three SNPs rs1051730, rs8034191 and rs569207 in
the nAChR cluster based on previous findings [9,11–13,31,32]. The
SNPs belong to the linkage-disequilibrium block containing nAChR
genes, but do not represent the overall CHRNA5-A3-B4 group.
Rs1051730 is a synonymous mutation and rs569207 an intronic
SNP belonging to the nAChR subunit genes, CHRNA3 and
CHRNA5 respectively, and the third SNP, rs8034191, is located
near nAChR subunit genes on 15q25 on LOC123688. Genotyping
was performed by K-Bioscience (UK) using their patent-protected
competitive allele specific PCR system (KASPar) (http://www.
kbioscience.co.uk/index.html).
Statistics
Data on smoking habits and lung function collected during the
surveys from 1965 to 1990 have been used for analyses. To study
the changes in smoking habits such as quitting smoking within
smokers and restarting smoking within ex-smokers, we compared
the information of two successive surveys. The paired observations
had a minimum interval of 3 years and every subject who had
smoked at any time contributed to the analyses with a maximum
of 7 paired observations. Analyses of the paired observations have
been performed separately for smokers and ex-smokers: To
investigate quitting smoking we selected all paired observations
in which the subject smoked at the first observation of 2 successive
surveys. The smoking habit (i.e. smoking or ex-smoking) at the
nearest follow-up survey (i.e. the second observation of two
successive surveys) was used as dependent variable in our analyses.
To investigate restarting smoking we selected all paired observa-
tions in which the subject was an ex-smoker at the first of 2
successive surveys. Again, the smoking habit (i.e. ex-smoking or
restarted smoking) at the nearest follow-up survey was the
dependent variable in our analyses.
1. SNPs in the nAChR cluster and changes in smoking
habits in smokers and ex-smokers
Generalized estimating equations (GEE) were used to investi-
gate in smokers and ex-smokers separately the associations of the
SNPs in the nAChR cluster with quitting and restarting smoking,
respectively. This method takes into account the dependence of
multiple measurements within one subject and adjusts for the fact
the intervals between the observations are not constant and the
number per subject was variable. In the GEE model, an OR.1
should be interpreted as an increased chance to stop or restart
smoking and an OR,1 should be interpreted as a decreased
chance to stop or restart smoking. In the GEE model, the smoking
habit was the dependent variable (categorical). We adjusted our
analyses for gender and the time between two successive surveys.
2. SNPs in the nAChR cluster and the annual FEV1 decline
in smokers and ex-smokers
Linear mixed-effects models (LME) were used in smokers and
ex-smokers separately to investigate the associations of the SNPs in
the nAChR cluster with the annual FEV1 decline (defined as the
difference in FEV1 between the 2
nd and 1
st observation of two
successive surveys divided by the time in years between these
surveys). In the LME model, the annual FEV1 decline was the
dependent variable (continuous). We adjusted our analyses for
gender, the time between two successive surveys and age and
height at the first of two successive surveys. Quitting and restarting
smoking were also used in the analyses as independent variables
for smokers respectively ex-smokers. In the LME model, a
negative regression coefficient should be interpreted as an excess
FEV1 decline per year and a positive regression coefficient as less
FEV1 decline per year as compared to the wildtype. In the LME
model effect estimates are considered significant if the confidence
interval does not include 0. Since E, estimated from the LME
model, can be interpreted as a regression coefficient, we indicated
nAChRs Variants, Smoking Habits and COPD
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presented results and ease of interpretation.
3. Changes in smoking habits and the annual FEV1
decline in smokers and ex-smokers
LME models were used to investigate the associations of
quitting and restarting smoking with the annual FEV1 decline
separately in smokers and ex-smokers. The analyses were adjusted
for gender, age and height at the first of two successive surveys and
the time between two successive surveys.
4. SNPs in the nAChR cluster and cigarettes smoked per
day, packyears and COPD at the last survey
We used linear regression to assess the associations of the SNPs
and number of cigarettes smoked per day at the last survey in
current smokers. The associations of the SNPs with packyears
were performed in ever smokers (current smokers and ex-smokers
together). We adjusted for age and gender. We used chi-square
tests to assess the differences in the prevalence of the SNPs
between subjects with (FEV1/FVC,70%) and without (FEV1/
FVC.70%) COPD. In the linear regression model, a negative
regression coefficient should be interpreted as a lower number of
cigarettes per day and less packyears, and a positive regression
coefficient should be interpreted as a higher number of cigarettes
per day and higher number of packyears.
To asses the associations of the SNPs in the nAChR cluster with
changes in smoking habits, with the annual FEV1 decline in
smokers and ex-smokers, and with the daily number of cigarettes
and packyears at the last survey we used the general genetic model
where heterozygote and homozygote variants were coded
separately as dummy variables and compared to the homozygote
wild type.
All analyses were performed using SPSS version 16.0 for
Windows and values of p,0.05 (tested 2-sided) were considered
statistically significant. Linkage Disequilibrium (LD) plots (a
threshold of 0.8 for the correlation coefficient (r
2) and Hardy
Weinberg Equilibrium (HWE) tests were performed with Haplo-
view (version 4.2) [33].
LME models were used with a random intercept at the subject
level, assuming data are missing at random. We included only
FEV1 measurements from the age of 30 years onwards because it
is assumed that the maximal lung function is reached before that
age and the FEV1 is considered to be either in the plateau or
decline phase [34].
Supporting Information
Figure S1 Linkage disequilibrium plot and correlation
coefficients (r
2) for 3 polymorphisms in the nAChR
cluster genotyped in Vlagtwedde-Vlaardingen cohort
(n=1,390). The location of the single nucleotide polymorphisms
is given for the HapMap Data Release February 2009.
(TIF)
Table S1 Prevalence of the nAChR SNPs in Vlagtwedde
– Vlaardingen. N=number of subjects.
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Table S2 The effect of the nAChR SNPs on smoking
habits in smokers (pairs=3393) and ex-smokers
(pairs=1468). GEE model, adjusted for gender, time between
2 consecutive available visits; a=heterozygote vs. wild-type;
b=homozygote variant vs. wild-type.
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Table S3 Annual FEV1 declines in smokers and ex-
smokers. Nr FEV1 declines refers to the total number of annual
FEV1 declines available; Nr. subjects refers to smokers or ex-
smokers who have at least 1 annual FEV1 decline available.
(DOCX)
Table S4 Differences in annual FEV1 decline according
to smoking status. B=regression coefficient; LME model
adjusted for gender, height and age at the first of two successive
surveys and time between two successive surveys. The results
showing a significant association are depicted in bold.
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